Paolo Calabrò: Lower LDL-C Variability With PCSK9 Inhibitors and Inclisira
Paolo Calabrò, Director of the Cardiovascular Department at S. Anna and S. Sebastiano Hospital, shared on LinkedIn:
”Reduction of visit-to-visit LDL-C intraindividual variability in patients treated with PCSK9 inhibitors and inclisiran vs standard lipid-lowering therapy.”
Title: Reduction of visit-to-visit LDL-C intraindividual variability in patients treated with PCSK9 inhibitors and inclisiran vs standard lipid-lowering therapy
Authors: Arturo Cesaro, Vincenzo Acerbo, Francesco Scialla, Andrea Zito, Gennaro Porcelli, Domenico Panico, Giovanni Argenziano, Demetrio Iaria, Maria Grazia Monaco, Vincenzo De Sio, Felice Gragnano, Michele Golino, Massimiliano Ruscica, Stefano Carugo, Alberto Corsini, Paolo Calabrò
Read the full article here.
Stay updated with Hemostasis Today.
-
Sep 13, 2026, 14:37Mohammad Zamrood Khan: Hereditary Spherocytosis and Protein C/S Deficiency Case Report Submitted
-
Sep 13, 2026, 14:33Heghine Khachatryan: A Resource-Adapted Approach to Hemophilia Joint Care
-
Sep 13, 2026, 14:23Simon Fletcher: The Unmet Burden of Factor VII Deficiency
-
Sep 13, 2026, 14:10Azusa Nagao: The Evolving Burden of Haemophilia Prophylaxis
-
Sep 13, 2026, 13:50Priya Sriskandarajah: The Challenge of Thrombotic Risk in Myeloproliferative Neoplasms
-
Sep 13, 2026, 12:31Vishakha K. Kumar: ISTH Opens Public Comment Period on New Guidance
-
Sep 13, 2026, 12:13Tahsin Ara Mim: Takayasu’s Arteritis Case Report Secures 2nd Runner-Up
-
Sep 13, 2026, 11:26Tareq Abadl: When Good Samples Give Bad Numbers – Spotting EDTA Contamination in the Lab
-
Sep 13, 2026, 11:22Amanda Unsworth: Gratitude and Next Steps as Leadership Transitions at The Platelet Society